News Releases

All of the latest news about our university. (by topic)

Bloomberg Businessweek ranks UB MBA No. 30 among public B-schools
10/2/24
Bloomberg Businessweek has again ranked the University at Buffalo School of Management’s MBA program one of the nation’s best.
Study: Stigma legitimizes unpaid labor as therapy, even for those doing the work
10/2/24
Rehab workers in the study who engaged in broad stigmatizing tropes about addiction were more likely to believe the “work therapy” — as it’s called by the Salvation Army — was beneficial.
UB expert Vincent Lynch says animal genes can help us understand human health
10/2/24
Evolutionary biologist joins Driven to Discover podcast to talk about his curiosity-driven research and why bringing back extinct species is a bad idea.
Study: For long COVID, lithium aspartate at low doses is ineffective, but higher doses may be promising
10/2/24
At low doses, lithium aspartate is ineffective in treating the fatigue and brain fog that is often a persistent feature of long COVID.
It all adds up: Study finds forever chemicals are more toxic as mixtures
10/1/24
The research also found that PFOA and PFOS are major contributors to toxicity
UB awarded $745,000 for a digital system to prevent e-cigarette use among adolescents
9/30/24
Eunhee Park aims to create a targeted e-cigarette use cessation intervention using a smartphone app.
UB researcher co-founds data/AI-driven software venture to revolutionize companies’ materials usage
9/30/24
An applied AI company, materialsIN leverages database infrastructure with advanced data processing.
UB program dubbed a ‘Hidden Gem’ according to national organization
9/27/24
UB’s Philosophy, Politics and Economics program garners recognition from the American Council of Trustees and Alumni.
How to deliver the most effective diversity training
9/27/24
Study finds results vary based on how the training is designed.
Results from study of first permanently implanted brain-computer interface will be presented at CNS
9/26/24
Elad Levy will present results of the clinical trial that assessed the safety of Synchron’s endovascular brain-computer interface in people with severe paralysis at the Congress of Neurological Surgeons (CNS).

Next> <Previous